Copyright Reports & Markets. All rights reserved.

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Professional Survey Report 2018

Request for Sample of this report
Buy now

Table of Contents

    Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Professional Survey Report 2017

      1 Report Overview

      • 1.1 Definition and Specification
      • 1.2 Report Overview
        • 1.2.1 Manufacturers Overview
        • 1.2.2 Regions Overview
        • 1.2.3 Type Overview
        • 1.2.4 Application Overview
      • 1.3 Industrial Chain
        • 1.3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Overall Industrial Chain
        • 1.3.2 Upstream
        • 1.3.3 Downstream
      • 1.4 Industry Situation
        • 1.4.1 Industrial Policy
        • 1.4.2 Product Preference
        • 1.4.3 Economic/Political Environment
      • 1.5 SWOT Analysis

      2 Market Analysis by Types

      • 2.1 Overall Market Performance(Volume)
        • 2.1.1 Preface Market Performance (Volume)
        • 2.1.2 Eluxadoline Market Performance (Volume)
        • 2.1.3 Alosetron Market Performance (Volume)
        • 2.1.4 Rifaximin Market Performance (Volume)
        • 2.1.5 Loperamide Market Performance (Volume)
      • 2.2 Overall Market Performance(Value)
        • 2.1.1 Preface Market Performance (Value)
        • 2.1.2 Eluxadoline Market Performance (Value)
        • 2.1.3 Alosetron Market Performance (Value)
        • 2.1.4 Rifaximin Market Performance (Value)
        • 2.1.5 Loperamide Market Performance (Value)

      3 Product Application Market

      • 3.1 Overall Market Performance (Volume)
        • 3.1.1 Hospitals Market Performance (Volume)
        • 3.1.2 Clinics Market Performance (Volume)
        • 3.1.3 Others Market Performance (Volume)

      4 Manufacturers Profiles/Analysis

      • 4.1 Astellas Pharmaceuticals
        • 4.1.1 Astellas Pharmaceuticals Profiles
        • 4.1.2 Astellas Pharmaceuticals Product Information
        • 4.1.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
        • 4.1.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
      • 4.2 Actavis
        • 4.2.1 Actavis Profiles
        • 4.2.2 Actavis Product Information
        • 4.2.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
        • 4.2.4 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
      • 4.3 Pfizer
        • 4.3.1 Pfizer Profiles
        • 4.3.2 Pfizer Product Information
        • 4.3.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
        • 4.3.4 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
      • 4.4 GlaxoSmithKline
        • 4.4.1 GlaxoSmithKline Profiles
        • 4.4.2 GlaxoSmithKline Product Information
        • 4.4.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
        • 4.4.4 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
      • 4.5 Salix Pharmaceuticals Ltd
        • 4.5.1 Salix Pharmaceuticals Ltd Profiles
        • 4.5.2 Salix Pharmaceuticals Ltd Product Information
        • 4.5.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
        • 4.5.4 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
      • 4.6 AstraZenenca
        • 4.6.1 AstraZenenca Profiles
        • 4.6.2 AstraZenenca Product Information
        • 4.6.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
        • 4.6.4 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status

      5 Market Performance for Manufacturers

      • 5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units) and Market Share by Manufacturers 2013-2018
      • 5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Market Share by Manufacturers 2013-2018
      • 5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Market Share by Manufacturers 2013-2018
      • 5.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 5.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
      • 5.6 Market Concentration

      6 Regions Market Performance for Manufacturers

      • 6.1 China Market Performance for Manufacturers
        • 6.1.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        • 6.1.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        • 6.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
        • 6.1.4 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
        • 6.1.5 Market Concentration
      • 6.2 USA Market Performance for Manufacturers
        • 6.2.1 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        • 6.2.2 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        • 6.2.3 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
        • 6.2.4 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
        • 6.2.5 Market Concentration
      • 6.3 Europe Market Performance for Manufacturers
        • 6.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        • 6.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        • 6.3.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
        • 6.3.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
        • 6.3.5 Market Concentration
      • 6.4 Japan Market Performance for Manufacturers
        • 6.4.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        • 6.4.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        • 6.4.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
        • 6.4.4 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
        • 6.4.5 Market Concentration
      • 6.5 Korea Market Performance for Manufacturers
        • 6.5.1 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        • 6.5.2 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        • 6.5.3 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
        • 6.5.4 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
        • 6.5.5 Market Concentration
      • 6.6 India Market Performance for Manufacturers
        • 6.6.1 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        • 6.6.2 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        • 6.6.3 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
        • 6.6.4 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
        • 6.6.5 Market Concentration
      • 6.7 Southeast Asia Market Performance for Manufacturers
        • 6.7.1 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        • 6.7.2 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        • 6.7.3 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
        • 6.7.4 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
        • 6.7.5 Market Concentration
      • 6.8 South America Market Performance for Manufacturers
        • 6.8.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        • 6.8.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        • 6.8.3 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
        • 6.8.4 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
        • 6.8.5 Market Concentration

      7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Performance (Sales Point)

      • 7.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units) and Market Share by Regions 2013-2018
      • 7.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Market Share by Regions 2013-2018
      • 7.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Market Share by Regions 2013-2018
      • 7.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Regions 2013-2018
      • 7.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin by Regions 2013-2018

      8 Development Trend for Regions (Sales Point)

      • 8.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
      • 8.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
      • 8.3 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
      • 8.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
      • 8.5 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
      • 8.6 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
      • 8.7 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
      • 8.8 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
      • 8.9 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018

      9 Development Trend for Regions (Sales Point)

      • 9.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
      • 9.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
      • 9.3 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
      • 9.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
      • 9.5 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
      • 9.6 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
      • 9.7 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
      • 9.8 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
      • 9.9 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018

      10 Upstream Source, Technology and Cost

      • 10.1 Upstream Source
      • 10.2 Technology
      • 10.3 Cost

      11 Channel Analysis

      • 11.1 Market Channel
      • 11.2 Distributors

      12 Consumer Analysis

      • 12.1 Hospitals Industry
      • 12.2 Clinics Industry
      • 12.3 Others Industry

      13 Market Forecast 2019-2024

      • 13.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
        • 13.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units) and Share by Regions 2019-2024
        • 13.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units) and Growth Rate 2019-2024
        • 13.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        • 13.1.4 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        • 13.1.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        • 13.1.6 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        • 13.1.7 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        • 13.1.8 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        • 13.1.9 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        • 13.1.10 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 13.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
        • 13.3.1 Overall Market Performance
        • 13.3.2 Preface Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        • 13.3.3 Eluxadoline Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        • 13.3.4 Alosetron Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        • 13.3.5 Rifaximin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 13.4 Sales by Application 2019-2024
        • 13.4.1 Overall Market Performance
        • 13.4.2 Hospitals Sales and and Growth Rate 2019-2024
        • 13.4.3 Clinics Sales and and Growth Rate 2019-2024
        • 13.4.4 Others Sales and and Growth Rate 2019-2024
      • 13.5 Price (USD/Unit) and Gross Profit
        • 13.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) Trend 2019-2024
        • 13.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Profit Trend 2019-2024

      14 Conclusion

      This report focuses on top manufacturers in global market, with Sales, price, revenue and market share for each manufacturer, covering
      Astellas Pharmaceuticals
      Actavis
      Pfizer
      GlaxoSmithKline
      Salix Pharmaceuticals Ltd
      AstraZenenca
      ...

      On the basis of product, this report displays the Sales, revenue, price, market share and growth rate of each type, primarily split into
      Preface
      Eluxadoline
      Alosetron
      Rifaximin
      Loperamide
      Diphenoxylate + Atropine
      ? ? Dicyclomine and Hyoscyamine

      By Application, the market can be split into
      China
      USA
      Europe
      Japan
      Korea
      India
      Southeast Asia
      South America

      By Regions, this report covers (we can add the regions/countries as you want)

      If you have any special requirements, please let us know and we will offer you the report as you want.

      Buy now